| Comprehensive agenda covering global regulatory strategy, clinical operations, AI-driven data, and investment trends
| Practical insights on FDA/EMA regulatory changes and digital transformation
| Industry, academia, and investment leaders discuss product- and market-specific strategies
| Event to be held on October 24 at Josun Palace Seoul Gangnam, featuring exclusive gifts and a lucky draw for preregistered attendees
JNPMEDI, a digital platform–driven consultancy for new drug and innovative medical device development, will host “2025 JNPMEDI CONNECT” on October 24 at Josun Palace Seoul Gangnam. Under the theme “RDC in Action: Accelerating Global Success in Life Science Innovation,” the event will explore practical, end-to-end strategies across regulatory affairs, clinical execution, AI-enabled data management, and life-science investment.
Now in its fourth year, the conference focuses on strategies and collaboration models that directly apply to real-world industry challenges. The program consists of four sessions led by frontline experts from regulatory, clinical, AI/data, and investment sectors.
The first session will highlight global regulatory trends, including updates from major authorities, FDA approval case studies, and product-specific market entry pathways. The second session will address multinational clinical trial operations, resource optimization, and platform-based execution models.
A third session will focus on AI-driven digital transformation in clinical development, covering AI drug discovery trends and CDISC-based data structuring. The final session will examine investment perspectives, open innovation models, global partnerships, and technology transfer strategies.
Speakers include opening remarks from Prof. Il-Seob Lee of CHA University and congratulatory remarks from Young-Min Park, Director of the Korea Drug Development Fund (KDDF). Additional presenters include faculty and industry leaders from Chung-Ang University, Medirama, Cowell Biodime, the Korean Society of Pharmaceutical Medicine, and representatives from key organizations such as the Korea Regulatory Science Center, GC Biopharma, AstraZeneca Korea, Sungkyunkwan University College of Pharmacy, the AI New Drug Development Institute, Solidus Investment, and Celltrion.
JNPMEDI CEO Kwunho Jeong emphasized that this year’s event aims to “bring together practitioners across the ecosystem to discuss real challenges and build actionable strategies,” highlighting the growing importance of connection and collaboration in global expansion.
On-site programs will include a photo zone, limited-edition gifts for preregistered participants, and a lucky draw.
Additional information and preregistration are available through JNPMEDI’s official website.
| Comprehensive agenda covering global regulatory strategy, clinical operations, AI-driven data, and investment trends
| Practical insights on FDA/EMA regulatory changes and digital transformation
| Industry, academia, and investment leaders discuss product- and market-specific strategies
| Event to be held on October 24 at Josun Palace Seoul Gangnam, featuring exclusive gifts and a lucky draw for preregistered attendees
JNPMEDI, a digital platform–driven consultancy for new drug and innovative medical device development, will host “2025 JNPMEDI CONNECT” on October 24 at Josun Palace Seoul Gangnam. Under the theme “RDC in Action: Accelerating Global Success in Life Science Innovation,” the event will explore practical, end-to-end strategies across regulatory affairs, clinical execution, AI-enabled data management, and life-science investment.
Now in its fourth year, the conference focuses on strategies and collaboration models that directly apply to real-world industry challenges. The program consists of four sessions led by frontline experts from regulatory, clinical, AI/data, and investment sectors.
The first session will highlight global regulatory trends, including updates from major authorities, FDA approval case studies, and product-specific market entry pathways. The second session will address multinational clinical trial operations, resource optimization, and platform-based execution models.
A third session will focus on AI-driven digital transformation in clinical development, covering AI drug discovery trends and CDISC-based data structuring. The final session will examine investment perspectives, open innovation models, global partnerships, and technology transfer strategies.
Speakers include opening remarks from Prof. Il-Seob Lee of CHA University and congratulatory remarks from Young-Min Park, Director of the Korea Drug Development Fund (KDDF). Additional presenters include faculty and industry leaders from Chung-Ang University, Medirama, Cowell Biodime, the Korean Society of Pharmaceutical Medicine, and representatives from key organizations such as the Korea Regulatory Science Center, GC Biopharma, AstraZeneca Korea, Sungkyunkwan University College of Pharmacy, the AI New Drug Development Institute, Solidus Investment, and Celltrion.
JNPMEDI CEO Kwunho Jeong emphasized that this year’s event aims to “bring together practitioners across the ecosystem to discuss real challenges and build actionable strategies,” highlighting the growing importance of connection and collaboration in global expansion.
On-site programs will include a photo zone, limited-edition gifts for preregistered participants, and a lucky draw.
Additional information and preregistration are available through JNPMEDI’s official website.